PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial-Reference-Cited by-全球学者库

登录注册会员服务联系我们

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

Published:2024-02 Issue:4 Volume:69 Page:535-543
ISSN:2095-9273
Container-title:Science Bulletin
language:en
Short-container-title:Science Bulletin

Author:

Maggie Liu Si-Yang,Huang Jie,Deng Jia-Yi,Xu Chong-Rui,Yan Hong-Hong,Yang Ming-Yi,Li Yang-Si,Ke E-E,Zheng Ming-Ying,Wang Zhen,Lin Jia-Xin,Gan Bin,Zhang Xu-Chao,Chen Hua-Jun,Wang Bin-Chao,Tu Hai-Yan,Yang Jin-Ji,Zhong Wen-Zhao,Li Yangqiu,Zhou Qing,Wu Yi-Long

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference26 articles.

1. Toward a cure for lung cancer: Important advances in operable non-small cell lung cancer;Liu;Sci Bull,2022

2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

3. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC;Cui;Sci Rep,2020

4. Comparative effectiveness of atezolizumab, nivolumab, and docetaxel in patients with previously treated non-small cell lung cancer;Ramagopalan;JAMA Netw Open,2021

5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前全球学者库共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP